ANRim was established in 2023. Its core team originates from City University of Hong Kong and possesses over ten years of research and development experience in nanotechnology and biotechnology. The company focuses on integrating nanotechnology with precision medicine, developing gene delivery and detection technologies based on nanoneedle array biochips, and has secured more than 20 patents.

‍

We are dedicated to advancing affordable next-generation cell therapy and gene editing solutions, aiming to become an innovative pioneer in this field.